Norris Medicines Ltd
Incorporated in 1990, Norris Medicines
Ltd is a manufacturer of Injections and
Medicinal formulations[1]
- Market Cap ₹ 14.0 Cr.
- Current Price ₹ 14.0
- High / Low ₹ 20.0 / 12.0
- Stock P/E
- Book Value ₹ -15.1
- Dividend Yield 0.00 %
- ROCE 3.36 %
- ROE %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 69.8 to 52.5 days.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -7.87% over past five years.
- Promoter holding is low: 34.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.68 | 18.86 | 20.46 | 13.57 | 16.26 | 7.84 | 12.25 | 9.44 | 8.36 | 5.64 | 5.82 | 8.13 | |
| 16.97 | 18.03 | 20.46 | 15.49 | 16.87 | 10.00 | 14.00 | 9.52 | 7.43 | 5.81 | 6.08 | 7.47 | |
| Operating Profit | 1.71 | 0.83 | 0.00 | -1.92 | -0.61 | -2.16 | -1.75 | -0.08 | 0.93 | -0.17 | -0.26 | 0.66 |
| OPM % | 9.15% | 4.40% | 0.00% | -14.15% | -3.75% | -27.55% | -14.29% | -0.85% | 11.12% | -3.01% | -4.47% | 8.12% |
| 0.15 | 0.30 | 0.06 | 0.14 | 0.04 | 0.09 | 0.05 | 0.03 | 0.01 | 0.01 | 0.06 | 0.05 | |
| Interest | 0.54 | 0.67 | 0.60 | 0.70 | 0.73 | 0.88 | 1.63 | 1.48 | 1.50 | 0.37 | 0.44 | 0.50 |
| Depreciation | 1.31 | 0.60 | 0.65 | 0.71 | 0.71 | 0.73 | 0.67 | 0.66 | 0.63 | 0.57 | 0.54 | 0.49 |
| Profit before tax | 0.01 | -0.14 | -1.19 | -3.19 | -2.01 | -3.68 | -4.00 | -2.19 | -1.19 | -1.10 | -1.18 | -0.28 |
| Tax % | 10,500.00% | -128.57% | -35.29% | -21.00% | -16.42% | -22.83% | 24.25% | 49.32% | 47.06% | 8.18% | 5.08% | 0.00% |
| -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | |
| EPS in Rs | -1.04 | 0.04 | -0.77 | -2.51 | -1.68 | -2.84 | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -8% |
| 3 Years: | -1% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 23% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 6% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Reserves | -4.63 | -4.60 | -5.36 | -7.88 | -9.55 | -12.39 | -17.36 | -20.62 | -22.37 | -23.56 | -24.79 | -25.07 |
| 8.16 | 7.51 | 7.57 | 7.71 | 11.24 | 17.92 | 15.52 | 21.08 | 21.40 | 21.52 | 21.58 | 21.53 | |
| 4.69 | 5.06 | 9.90 | 10.92 | 8.76 | 5.10 | 11.69 | 3.80 | 4.72 | 6.29 | 7.09 | 6.50 | |
| Total Liabilities | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
| 8.61 | 8.34 | 9.97 | 9.32 | 8.90 | 8.25 | 7.67 | 7.07 | 6.47 | 5.79 | 5.27 | 4.79 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 9.53 | 9.55 | 12.06 | 11.35 | 11.47 | 12.30 | 12.10 | 7.11 | 7.20 | 8.38 | 8.53 | 8.09 | |
| Total Assets | 18.15 | 17.90 | 22.04 | 20.68 | 20.38 | 20.56 | 19.78 | 14.19 | 13.68 | 14.18 | 13.81 | 12.89 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.43 | 1.35 | -0.96 | 0.80 | -1.92 | -2.88 | 1.11 | -1.01 | 1.20 | 0.17 | 0.51 | 0.58 | |
| -0.88 | -0.34 | -2.05 | -0.08 | -0.29 | 0.00 | -0.06 | -0.09 | -0.02 | 0.05 | 0.00 | -0.08 | |
| 0.10 | -1.32 | 3.16 | -0.66 | 2.18 | 2.86 | -1.09 | 1.10 | -1.18 | -0.20 | -0.50 | -0.52 | |
| Net Cash Flow | -2.21 | -0.31 | 0.15 | 0.06 | -0.02 | -0.02 | -0.04 | 0.00 | 0.00 | 0.02 | 0.00 | -0.02 |
| Free Cash Flow | -2.30 | 1.03 | -3.24 | 0.74 | -2.21 | -2.96 | 1.02 | -1.07 | 1.17 | 0.26 | 0.49 | 0.57 |
| CFO/OP | -84% | 163% | -42% | 315% | 133% | -63% | 1,262% | 129% | -100% | -196% | 88% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73.66 | 53.61 | 84.20 | 66.44 | 67.57 | 128.49 | 53.33 | 42.15 | 48.03 | 68.60 | 88.43 | 52.53 |
| Inventory Days | 100.05 | 134.23 | 129.50 | 238.53 | 134.81 | 323.82 | 212.99 | 157.45 | 347.62 | 594.15 | 436.94 | 337.84 |
| Days Payable | 111.66 | 99.30 | 125.29 | 252.40 | 139.83 | 233.37 | 218.83 | 86.53 | 149.91 | 244.25 | 271.90 | 222.40 |
| Cash Conversion Cycle | 62.06 | 88.54 | 88.41 | 52.56 | 62.55 | 218.94 | 47.49 | 113.06 | 245.73 | 418.51 | 253.47 | 167.97 |
| Working Capital Days | 27.75 | 34.84 | -16.06 | -91.18 | -32.55 | -30.73 | -103.69 | -97.82 | -122.25 | -202.56 | -241.45 | -167.91 |
| ROCE % | 4.02% | 4.03% | -4.08% | -22.92% | -11.97% | -20.68% | -20.13% | -7.68% | 3.20% | -8.43% | -10.13% | 3.36% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Export Revenue (FOB Basis) INR Lacs |
|
||||||
| Number of Manufacturing Plants Number |
|||||||
| Number of Permanent Employees Number |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Board approved audited FY2026 results on May 30, 2026 and appointed internal auditor for FY2026-27.
- Outcome Of Board Meeting Held Today I.E. 30Th May, 2026. 30 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 30Th May, 2026.
30 May - Board approved FY2026 audited results and appointed Dhiren Y Parikh & Co. as internal auditor.
-
Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements), 2015 For Holding Board Meeting For Approval Of Audited Financial Results For The Quarter And Year Ended March 31, 2026 And Other Matters.
25 May - Board to approve audited FY2025-26 results on 30 May 2026; trading window closed since 1 April 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 20 Apr
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2000
from bse
-
Financial Year 1998
from bse
Business Overview:[1]
NML is engaged in the healthcare business.
It carries out contract manufacturing and License Manufacturing for large Multinational
and big Indian Pharma Companies.